Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma

Next Previous
X
Search
Trial Profile

A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Asthma; Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Acronyms RELAX
  • Sponsors AstraZeneca

    • Most Recent Events

    • 28 Jan 2010 Results published in the American Journal of Respiratory and Critical Care Medicine.
    • 30 May 2009 Results presented at Digestive Disease Week (DDW) 2009.
    • 26 Feb 2008 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top